267 related articles for article (PubMed ID: 17229747)
21. Effect of steroid treatment in cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
Virgilio R; Corti S; Agazzi P; Santoro D; Lanfranconi S; Candelise L; Bresolin N; Comi GP; Bersano A
J Neurol Neurosurg Psychiatry; 2009 Jan; 80(1):95-6. PubMed ID: 19091718
[No Abstract] [Full Text] [Related]
22. Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies.
Vianello M; Tavolato B; Armani M; Giometto B
Cerebellum; 2003; 2(1):77-9. PubMed ID: 12882238
[TBL] [Abstract][Full Text] [Related]
23. Experience with immunotherapy in 3 patients with cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies.
Rouco I; Hurtado P; Castaño L; Zarranz JJ
Neurologia; 2015 May; 30(4):247-9. PubMed ID: 24075582
[No Abstract] [Full Text] [Related]
24. Neurological disorders associated with glutamic acid decarboxylase antibodies: a Brazilian series.
Fernandes M; Munhoz RP; Carrilho PE; Arruda WO; Lorenzoni PJ; Scola RH; Werneck LC; Teive HA
Arq Neuropsiquiatr; 2012 Sep; 70(9):657-61. PubMed ID: 22990719
[TBL] [Abstract][Full Text] [Related]
25. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.
Honnorat J; Saiz A; Giometto B; Vincent A; Brieva L; de Andres C; Maestre J; Fabien N; Vighetto A; Casamitjana R; Thivolet C; Tavolato B; Antoine J; Trouillas P; Graus F
Arch Neurol; 2001 Feb; 58(2):225-30. PubMed ID: 11176960
[TBL] [Abstract][Full Text] [Related]
26. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies.
Muñiz-Castrillo S; Vogrig A; Joubert B; Pinto AL; Gonçalves D; Chaumont H; Rogemond V; Picard G; Fabien N; Honnorat J
Cerebellum; 2020 Oct; 19(5):715-721. PubMed ID: 32592031
[TBL] [Abstract][Full Text] [Related]
27. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia.
Takenoshita H; Shizuka-Ikeda M; Mitoma H; Song S; Harigaya Y; Igeta Y; Yaguchi M; Ishida K; Shoji M; Tanaka M; Mizusawa H; Okamoto K
J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):386-9. PubMed ID: 11181864
[TBL] [Abstract][Full Text] [Related]
28. [Stiff-person syndrome and other neurological disorders associated with anti-GAD antibodies].
Hijazi J; Bedat-Millet AL; Hannequin D
Rev Med Interne; 2010 Jan; 31(1):23-8. PubMed ID: 19828214
[TBL] [Abstract][Full Text] [Related]
29. Anti-GAD Antibodies and the Cerebellum: Where Do We Stand?
Manto M; Mitoma H; Hampe CS
Cerebellum; 2019 Apr; 18(2):153-156. PubMed ID: 30343467
[TBL] [Abstract][Full Text] [Related]
30. The neurological syndromes associated with glutamic acid decarboxylase antibodies.
Baizabal-Carvallo JF
J Autoimmun; 2019 Jul; 101():35-47. PubMed ID: 31000408
[TBL] [Abstract][Full Text] [Related]
31. Response to steroid treatment in anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia, stiff person syndrome and polyendocrinopathy.
Kim JY; Chung EJ; Kim JH; Jung KY; Lee WY
Mov Disord; 2006 Dec; 21(12):2263-4. PubMed ID: 17013903
[No Abstract] [Full Text] [Related]
32. Acute Cerebellar Ataxia Associated with Anti-glutamic Acid Decarboxylase Antibodies Mimicking Miller Fisher Syndrome.
Nakamura Y; Nakajima H; Hosokawa T; Yamane K; Ishida S; Kimura F
Intern Med; 2018 Jan; 57(2):269-271. PubMed ID: 29093402
[TBL] [Abstract][Full Text] [Related]
33. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of patients with cerebellar ataxia associated with anti-GAD antibodies.
Aguiar TS; Fragoso A; Albuquerque CR; Teixeira PF; Souza MV; Zajdenverg L; Alves-Leon SV; Rodacki M; Lima MA
Arq Neuropsiquiatr; 2017 Mar; 75(3):142-146. PubMed ID: 28355320
[TBL] [Abstract][Full Text] [Related]
35. Gravity-Independent Upbeat Nystagmus in Syndrome of Anti-GAD Antibodies.
Feldman D; Otero-Millan J; Shaikh AG
Cerebellum; 2019 Apr; 18(2):287-290. PubMed ID: 30136028
[TBL] [Abstract][Full Text] [Related]
36. Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy.
Pedroso JL; Braga-Neto P; Dutra LA; Barsottini OG
Arq Neuropsiquiatr; 2011 Dec; 69(6):993. PubMed ID: 22297896
[No Abstract] [Full Text] [Related]
37. Neurological Syndromes Associated with Anti-GAD Antibodies.
Dade M; Berzero G; Izquierdo C; Giry M; Benazra M; Delattre JY; Psimaras D; Alentorn A
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456344
[TBL] [Abstract][Full Text] [Related]
38. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.
Peltola J; Kulmala P; Isojärvi J; Saiz A; Latvala K; Palmio J; Savola K; Knip M; Keränen T; Graus F
Neurology; 2000 Jul; 55(1):46-50. PubMed ID: 10891904
[TBL] [Abstract][Full Text] [Related]
39. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase.
Ishida K; Mitoma H; Song SY; Uchihara T; Inaba A; Eguchi S; Kobayashi T; Mizusawa H
Ann Neurol; 1999 Aug; 46(2):263-7. PubMed ID: 10443895
[TBL] [Abstract][Full Text] [Related]
40. [Anti-GAD antibodies in paraneoplastic cerebellar ataxia associated with limbic encephalitis and autonomic dysfunction].
Carra-Dalliere C; Thouvenot E; Bonafé A; Ducray F; Touchon J; Charif M
Rev Neurol (Paris); 2012 Apr; 168(4):363-6. PubMed ID: 22405456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
